dc.creator | Sakkas L.I. | en |
dc.date.accessioned | 2023-01-31T09:53:10Z | |
dc.date.available | 2023-01-31T09:53:10Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.31138/mjr.30.3.139 | |
dc.identifier.issn | 24593516 | |
dc.identifier.uri | http://hdl.handle.net/11615/78712 | |
dc.description.abstract | [No abstract available] | en |
dc.language.iso | en | en |
dc.source | Mediterranean Journal of Rheumatology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137961503&doi=10.31138%2fmjr.30.3.139&partnerID=40&md5=bf933ad09580ea1af6811a5cc7986002 | |
dc.subject | abatacept | en |
dc.subject | corticosteroid derivative | en |
dc.subject | infliximab | en |
dc.subject | rituximab | en |
dc.subject | tocilizumab | en |
dc.subject | tofacitinib | en |
dc.subject | tumor necrosis factor antibody | en |
dc.subject | antisynthetase syndrome | en |
dc.subject | aortic arch syndrome | en |
dc.subject | Article | en |
dc.subject | Crohn disease | en |
dc.subject | DAS28 | en |
dc.subject | drug efficacy | en |
dc.subject | Greece | en |
dc.subject | health maintenance organization | en |
dc.subject | human | en |
dc.subject | interstitial lung disease | en |
dc.subject | ischemic heart disease | en |
dc.subject | Israel | en |
dc.subject | pleura effusion | en |
dc.subject | Pneumocystis pneumonia | en |
dc.subject | prescription | en |
dc.subject | pulmonary hypertension | en |
dc.subject | remission | en |
dc.subject | rheumatic disease | en |
dc.subject | rheumatoid arthritis | en |
dc.subject | rheumatology | en |
dc.subject | scientific literature | en |
dc.subject | survival rate | en |
dc.subject | systemic lupus erythematosus | en |
dc.subject | systemic sclerosis | en |
dc.subject | treatment response | en |
dc.subject | Greek Rheumatology Society and Professional Association of Rheumatologists | en |
dc.title | Mediterranean Journal of Rheumatology September 2019 issue highlights | en |
dc.type | journalArticle | en |